drugset / Trial / NCT00473577
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose (MTD) of CRA-024781 IV given by 2-hour intravenous infusions in patients with refractory solid or hematologic malignancies. To evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, and to evaluate bioavailability of CRA-024781 IV when administered in a single oral dose.
Timeline
- Start
- 2005-08
- Primary completion
- 2007-11
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abexinostat | Small molecule | — | Intravenous |